BECOME A DIVISIVE ISSUE. TONIGHT, MORE THAN A DOZEN STICKERS LIKE THESE, NOW REMOVED FROM LIGHT POLES AND STREET SIGNS ACROSS HARVARD’S CAMPUS. THE STICKERS RESEMBLE AN ALTERED ISRAELI FLAG.

We may earn commission if you buy from a link. Why Trust Us? This must be the gold age of stickers and decals. They’re on everything from fruits and vegetables to durable goods and clothing.

Tara Bancroft’s rating is based on the promising potential of TG Therapeutics’ Briumvi in the anti-CD20 relapsing multiple sclerosis (RMS) market. Briumvi has shown remarkable efficacy with an ...

Many will have left their polling location with that modest icon of civic participation: the "I Voted" sticker. "I Voted" stickers come in different shapes, sizes and designs across the country.

TG Therapeutics stock rose Wednesday after the biotech company said 92% of patients who took its multiple sclerosis drug, Briumvi, didn't progress to disability after five years. Please watch the ...

TG Therapeutics, Inc. reported a modest Q3 beat and raised the full-year net sales guidance range for Briumvi by $7.5 million at the mid-point. The results were slightly underwhelming but ...

TG Therapeutics' Q3 earnings missed EPS expectations, primarily due to higher non-cash compensation and increased R&D investments, despite Briumvi's revenue growth. Briumvi, a CD20-directed ...

Third quarter 2024 U.S. BRIUMVI net revenue of $83.3 million Raises full year 2024 U.S. BRIUMVI net revenue target to $300 - $305 million Conference call to be held today, November 4, 2024 ...

U.S. net revenue from Briumvi grew by more than 230% year over year to $83.3 million. Total revenue for Q3 of $83.9 million surpassed analysts' expectations of $81.7 million. Diluted earnings per ...

The Nasdaq-listed firm recorded just over $50 million in BRIUMVI net revenue in the United States – also ahead of the management’s guidance. TG Therapeutics stock is still down 15% versus its ...

NEW YORK, Nov. 04, 2024 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ: TGTX) (the Company or TG Therapeutics) today announced its financial results for the third quarter of 2024, along with ...